BackGlenmark receives $4 million from Forest Lab as research fee
Glenmark has received $4 million as research fee for the development of novel mPGES-1 inhibitors to treat chronic inflammatory conditions
Premium
New Delhi: Glenmark Pharmaceuticals has received $4 million as research fee from Forest Laboratories Inc for drug development, taking the total amount received from the US-based firm to $15 million so far, the company said on Tuesday.
The company through its Swiss unit has received $4 million as research fee payment from Forest Laboratories Inc for the development of novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain, it said.
This collaborative agreement between the two companies was inked in 2012.
Under the terms of the agreement signed in FY 2012-13, Forest made $6 million upfront payment and also provided an additional $3 million to support the next phase of work, Glenmark Pharmaceuticals said in a statement.
In September 2013, Glenmark received an additional amount of $2 million as research fee payment from Forest Laboratories Inc.
“Hence, the total amount received by Glenmark from Forest Laboratories Inc towards its novel mPEGS-1 inhibitors programme is $15 million," the company said.
Glenmark shares were trading at Rs582.25 apiece on the BSE in afternoon trade, up 0.15% from its previous close.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!
